Aetna is taking legal action against Pfizer, Novartis, Teva Pharmaceuticals and others, saying the list of drugmakers ...

To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug ...

This may start to bring down the cost of brand-name competitors—here's who might get access, and one major difference from ...

Patients would pay no more than $25 for certain name-brand medications to treat chronic illnesses, including insulin for ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies to produce Victoza, also known as liraglutide, following a proposal by the ...

The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...

The Company has been granted Competitive Generic Therapy designation, which allows for 180 days of marketing exclusivity.

The bill would add scrutiny to pharmacy benefit managers and eliminate or cap out-of-pocket costs for drugs that treat ...

The legislative rush provided another example of state lawmakers struggling to reach consensus on significant policy matters, ...

President-elect Trump’s plan to enact heavy tariffs on certain imports could affect the prices and availability of ...